問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
洪啟盛
下載
2025-10-01 - 2030-06-30
Condition/Disease
• The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.
Test Drug
BI 690517 (Vicadrostat) or matching placebo Empagliflozin
Participate Sites13Sites
Recruiting13Sites
2024-09-01 - 2028-12-31
Participate Sites16Sites
Recruiting16Sites
2026-06-01 - 2030-06-30
Participate Sites14Sites
Recruiting14Sites
2025-03-01 - 2030-06-30
Participate Sites18Sites
Recruiting18Sites
2023-10-01 - 2026-12-31
Participate Sites9Sites
Not yet recruiting4Sites
Recruiting5Sites
2024-02-01 - 2028-12-31
Participate Sites11Sites
Recruiting11Sites
2022-06-01 - 2024-12-31
Participate Sites12Sites
Recruiting8Sites
2023-03-01 - 2027-02-28
Participate Sites17Sites
Recruiting17Sites
2025-07-01 - 2028-05-31
Participate Sites5Sites
2020-03-17 - 2024-05-02
Participate Sites8Sites
Not yet recruiting2Sites
Recruiting6Sites
全部
